Mediwound (NASDAQ: MDWD) has received a $ 11.00 price target from Wells Fargo & Co analysts in a research report issued to customers and investors on Wednesday, August 8th. The brokerage currently has a "buy" rating on the shares of the biopharmaceutical company. The price target of Wells Fargo & Co indicates a possible benefit of 71.88% of the current price of the company.
A number of other equity analysts have also commented on MDWD. ValuEngine raised Mediwound from a "strong sales" rating to a "sell" rating on Friday 11 May in a research note. Oppenheimer set a price target of $ 14.00 on Mediwound and gave the shares a "buy" rating in a research note on Tuesday, August 7th. Finally, Zacks Investment Research Mediwound reduced from a "hold" classification to a "sell" assessment in a research report on Wednesday 11 July. One research analyst has assessed the shares with a sell-rating, one has given a hold rating and five have given a buy-rating to the shares. The company currently has a consensus score of "buy" and an average price target of $ 9.79.
NASDAQ MDWD swapped $ 0.05 during trading on Wednesday and reached $ 6.40. The company's shares had a trading volume of 7,200 shares, compared to the average volume of 39,946. Mediwound has a low of 52 weeks of $ 3.56 and a height of 52 weeks of $ 7.35. The company has a market capitalization of $ 173.11 million, a P / E ratio of -10.32 and a beta of -0.16.
Mediwound (NASDAQ: MDWD) last released the quarterly results on Tuesday 7 August. The biopharmaceutical company reported ($ 0.15) earnings per share for the quarter, above the Thomson Reuters & # 39; consensus estimate of ($ 0.20) with $ 0.05. The company had sales of $ 1.03 million for the quarter compared with analyst estimates of $ 0.96 million. Mediwound had a negative return on equity of 210.90% and a negative net margin of 783.30%. sell-side analysts expect Mediwound to pay out -0.71 per share for the current year.
Institutional investors have recently changed their positions in the company. Migdal Insurance & Financial Holdings Ltd. increased its participations in Mediwound by 1.0% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,098,277 shares of the biopharmaceutical company's share of $ 14,478,000 after acquiring another 21,559 shares in the last quarter. Wells Fargo & Company MN increased its position in Mediwound shares by 84.6% in the fourth quarter. Wells Fargo & Company MN now owns 101,189 shares in shares of the biopharmaceutical company worth $ 450,000 after the purchase of an additional 46,666 shares during the period. Renaissance Technologies LLC strengthened its position in Mediwound shares by 18.2% in the fourth quarter. Renaissance Technologies LLC now owns 100,600 shares of the company's biopharmaceutical company worth $ 448,000 after buying another 15,500 shares during the period. Finally, in the second quarter, Nexthera Capital LP acquired a new position in Mediwound shares worth approximately $ 308,000. Institutional investors hold 32.94% of the company's shares.
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, producing and commercializing new therapeutic products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep, partial and complete thermal burns in the European Union, Israel and Argentina.
Recommended story: hedge funds
Receive news and ratings for Mediwound Daily – Enter your email address below to receive a concise, daily summary of the latest news and analyst ratings for Mediwound and related companies with the FREE daily email newsletter from MarketBeat.com.